SOHO State of the Art Updates and Next Questions | Sequencing Therapies in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Evidence, Challenges, and Opportunities for Cure - PubMed
6 hours ago
- #CAR T-cell therapy
- #Relapsed/refractory DLBCL
- #Bispecific antibodies
- The therapeutic landscape for relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) has evolved with novel agents and immunotherapies like bispecific antibodies and CAR T-cell therapies.
- Treatment sequencing in R/R DLBCL has become complex, influenced by relapse timing and patient-specific factors such as eligibility and access to CAR T-cell therapy.
- This review summarizes pivotal clinical trials informing current treatment strategies and discusses evolving approaches to optimize curative potential in R/R DLBCL.